Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

In an interview with Yahoo Finance, Deutsche Bank analyst James Shin singled out Roche’s (OTCMKTS: RHHBY) drug “CT-996” when asked about which oral weight loss drug he sees as the biggest ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply ...

Roche released topline results from the ongoing multi-part Phase 1 trial for CT-996, showing data better compared to existing competitors. Despite Novo Nordisk and Eli Lilly’s strong market ...

While Eli Lily has the injectable Zepbound. Roche is working on CT-996. UK-based AstraZeneca is also working on ECC5004. In fact, recently, the aforementioned Novo Nordisk also hit a goldmine with ...

The acquisition added a differentiated incretin portfolio with three candidates — CT-388, CT-996 and CT-868 — in its pipeline. However, the stock took a hit last month when RHHBY presented ...